File(s) not publicly available
Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV)
Version 2 2024-06-13, 14:17
Version 1 2021-01-13, 15:12
conference contribution
posted on 2024-06-13, 14:17 authored by M Khasraw, LE Abrey, AB Lassman, A Hormigo, C Nolan, IT Gavrilovic, IK Mellinghoff, AS Reiner, LM DeAngelis, AM OmuroPhase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV)
